Patent: 9,506,069
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Summary for Patent: 9,506,069
Title: | Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization |
Abstract: | Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof. |
Inventor(s): | Ambati; Balamurali K. (Sandy, UT), Uehara; Hironori (Salt Lake City, UT) |
Assignee: | University of Utah Research Foundation (Salt Lake City, UT) |
Application Number: | 14/394,726 |
Patent Claims: | see list of patent claims |
Details for Patent 9,506,069
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Sign Up | 2032-04-19 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Sign Up | 2032-04-19 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Sign Up | 2032-04-19 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |